| Oct 9 |
Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ...
|
| Oct 4 |
Moleculin to Present at Two Upcoming Investor Conferences
|
| Sep 23 |
Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma
|
| Sep 16 |
Moleculin Participates in Virtual Investor "What this Means" Segment
|
| Sep 9 |
Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma
|
| Aug 26 |
Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
|
| Aug 19 |
Moleculin Announces Closing of up to $16.5 Million Public Offering
|
| Aug 16 |
Moleculin prices up to $16.5M public offering
|
| Aug 16 |
Moleculin Announces Pricing of up to $16.5 Million Public Offering
|
| Aug 15 |
Moleculin Biotech GAAP EPS of -$1.70 beats by $0.74
|
